| Identification | Back Directory | [Name]
STL1267 | [CAS]
1429024-58-7 | [Synonyms]
STL1267
1,2,4-Triazolo[4,3-b]pyridazine, 6-([1,1'-biphenyl]-2-yloxy)-3-chloro- | [Molecular Formula]
C17H11ClN4O | [MOL File]
1429024-58-7.mol | [Molecular Weight]
322.75 |
| Hazard Information | Back Directory | [Uses]
STL1267 is a potent and cross-the-blood-brain barrier REV-ERB agonist with a Ki value of 0.16 μM for REV-ERBα. STL1267 shows no cytotoxicity. STL1267 inhibits the gene expression of BMAL1[1]. | [in vivo]
STL1267 (50 mg/kg; i.p.; once) inhibits Bmal1 expression in mouse[1]. | Animal Model: | 6-8 weeks, male C57Bl/6?J mice[1] | | Dosage: | 50 mg/kg | | Administration: | I.p.; once | | Result: | Showed a plasma half-life of 1.6 h, effectively suppressed BMAL1 expression in the liver at 12?h post-administration. |
| [References]
[1] Murray MH, et al. Structural basis of synthetic agonist activation of the nuclear receptor REV-ERB. Nat Commun. 2022 Nov 21;13(1):7131. DOI:10.1038/s41467-022-34892-4 |
|
| Company Name: |
Biorbyt Ltd.
|
| Tel: |
+44 (0)1223 859 353 |
| Website: |
http://www.biorbyt.com |
|